Head and neck cancers start in the organs of the head or neck such as mouth, throat, and lips. As with all cancer treatment development, a predictive preclinical model is needed for therapy evaluation. Patient-derived xenograft (PDX) models present a true representation of the human heterogeneity and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. Crown Bioscience has a large collection of head and neck cancer PDX models, including many with EGFR amplification. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.